Valproate:: A reappraisal of its pharmacodynamic properties and mechanisms of action

被引:433
作者
Löscher, W [1 ]
机构
[1] Sch Vet Med, Dept Pharmacol Toxicol & Pharm, D-30559 Hannover, Germany
关键词
D O I
10.1016/S0301-0082(98)00075-6
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Valproate is currently one of the major antiepileptic drugs with efficacy for the treatment of both generalized and partial seizures in adults and children. Furthermore, the drug is increasingly used for therapy of bipolar and schizoaffective disorders, neuropathic pain and fur prophylactic treatment of migraine. These various therapeutic effects are reflected in preclinical models, including a variety of animal models of seizures or epilepsy. The incidence of toxicity associated with the clinical use of valproate is low, but two rare toxic effects, idiosyncratic fatal hepatotoxicity and teratogenicity, necessitate precautions in risk patient populations. Studies from animal models on structure-relationships indicate that the mechanisms leading to hepatotoxicity and teratogenicity are distinct and also differ from the mechanisms of anticonvulsant action of valproate. Because of its wide spectrum of anticonvulsant activity against different seizure types, it has repeatedly been suggested that valproate acts through a combination of several mechanisms. As shown in this review, there is substantial evidence that valproate increases GABA synthesis and release and thereby potentiates GABAergic functions in some specific brain regions, such as substantia nigra, thought to be involved in the control of seizure generation and propagation. Furthermore, valproate seems to reduce the release of the epileptogenic amino acid gamma-hydroxybutyric acid and to attenuate neuronal excitation induced by NMDA-type glutamate receptors. In addition to effects on amino acidergic neurotransmission; valproate exerts direct effects on excitable membranes, although the importance of this action is equivocal. Microdialysis data suggest that valproate alters dopaminergic and serotonergic functions. Valproate is metabolized to several pharmacologically active metabolites, but because of the low plasma and brain concentrations of these compounds it is not likely that they contribute significantly to the anticonvulsant and toxic effects of treatment with the parent drug. By the experimental observations summarized in this review, most clinical effects of valproate can be explained, although much remains to be learned at a number of different levels of valproate's mechanisms of action. (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:31 / 59
页数:29
相关论文
共 239 条
[1]   QUANTITATIVE STRUCTURE ANTICONVULSANT ACTIVITY RELATIONSHIPS OF VALPROIC ACID, RELATED CARBOXYLIC-ACIDS AND TETRAZOLES [J].
ABBOTT, FS ;
ACHEAMPONG, AA .
NEUROPHARMACOLOGY, 1988, 27 (03) :287-294
[2]  
Adkison KDK, 1996, J PHARMACOL EXP THER, V276, P1189
[3]   DISTRIBUTION OF UNSATURATED METABOLITES OF VALPROATE IN HUMAN AND RAT-BRAIN - PHARMACOLOGICAL RELEVANCE [J].
ADKISON, KDK ;
OJEMANN, GA ;
RAPPORT, RL ;
DILLS, RL ;
SHEN, DD .
EPILEPSIA, 1995, 36 (08) :772-782
[4]   Electrophysiologic analysis of the actions of valproate on pyramidal neurons in the rat hippocampal slice [J].
Albus, H ;
Williamson, R .
EPILEPSIA, 1998, 39 (02) :124-139
[5]   EFFECTS OF VALPROATE IN A MODEL NERVOUS-SYSTEM (BUCCAL GANGLIA OF HELIX-POMATIA) .1. ANTIEPILEPTIC ACTIONS [J].
ALTRUP, U ;
GERLACH, G ;
REITH, H ;
SAID, MN ;
SPECKMANN, EJ .
EPILEPSIA, 1992, 33 (04) :743-752
[6]  
[Anonymous], 1981, Epilepsia, V22, P489
[7]   PROPOSAL FOR REVISED CLASSIFICATION OF EPILEPSIES AND EPILEPTIC SYNDROMES [J].
不详 .
EPILEPSIA, 1989, 30 (04) :389-399
[8]  
BAF MHM, 1994, NEUROCHEM INT, V24, P67
[9]  
BAILLIE TA, 1991, IDIOSYNCRATIC REACTI, P19
[10]  
Baillie Thomas A., 1995, P589